ArticleJournal of general internal medicine2026
Patient Profiles of Buprenorphine Initiators in General Healthcare Settings: A Latent Class Approach.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBuprenorphine is the most commonly used medication for treating opioid use disorder (OUD). It may also be beneficial for individuals with chronic pain who are physically dependent on opioids but do not meet the criteria for OUD. Therefore, the buprenorphine patient population may be heterogeneous in terms of OUD and comorbidities.
objectivesTo characterize the heterogeneity of patient profiles among those initiating buprenorphine treatment in a large multi-state healthcare system, focusing on comorbid pain, psychiatric, and substance use disorder diagnoses, and other patient characteristics associated with profiles.
designRetrospective cohort study using electronic health record data. PARTCIPIPANTS: Patients with at least 12 months of data before a new buprenorphine prescription (OUD formulation) and at least 6 months of follow-up. MAIN MEASURES: Presence vs absence of opioid use disorder diagnoses and latent class profiles of comorbid diagnoses and clinical characteristics. Post-index outcomes, including the number of buprenorphine orders and incidence of drug-related poisoning, were assessed for each class. KEY
resultsIn a cohort of 5726 individuals (mean age 38.6 years, 56.2% female, 84.0% white), four latent classes were identified: (1) high multimorbidity burden; (2) moderate multimorbidity burden; (3) high rates of comorbid pain diagnoses but lower rates of psychiatric and substance use disorder diagnoses, with most patients lacking opioid use disorder diagnoses; (4) lower rates of pain diagnoses but high rates of comorbid psychiatric and substance use disorder diagnoses. Post-index measures aligned well with comorbidity profiles.
conclusionPatients receiving buprenorphine in general healthcare settings likely form a heterogeneous group. This includes a subgroup with low rates of opioid use disorder diagnoses (class 2, pain comorbidity), who may resemble chronic pain patients more than conventional OUD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.